An Evidence-Graded Framework for Pharmaceutical Route Selection and Process-Risk Prioritization: A PN6047 Case Study
- 1Independent researcher
Abstract
Purpose: To develop and demonstrate an evidence-graded framework for screening discovery-scale synthetic routes before experimental process development, using the publicly disclosed route to PN6047, a clinical-stage δ-opioid receptor agonist, as a case study. Methods: No synthesis was performed. Operations exemplified in two patent documents were inventoried; each transformation and its conditions were graded A–D by the strength of public evidence; documented regulatory and hazard attributes were flagged; two process-oriented variants were screened by step count, flags and an evidence-weighted validation burden; and a twelve-item risk register was ranked, with the sensitivity of the prioritization to the author-assigned ratings tested by perturbation. Results: The exemplified route (milligram to gram scale; final N-functionalization isolated in 16% by preparative HPLC) carries 11 documented flags, including an ICH Q3C Class 1 solvent, palladium and a benzotriazole-derived coupling reagent. Variants R1 and R2 carry 3 flags each but a higher validation burden (11 and 15 against 2, linear scale): fewer documented flags did not mean lower development uncertainty. Two risks, impurity purge when crystallization replaces chromatography and the undisclosed route to the vinyl bromide, stayed in the top three in about 87% of perturbations, conditional on the initial risk model. Conclusion: The framework converts public route information into an auditable experimental-prioritization strategy while explicitly separating documented process liabilities from unvalidated alternatives. It does not select a best route; it shows where the evidence is strong or assumed and which experiments carry the highest information value.
Related
- Commit: Automated Scale-Up Crystallisation DataFactory for model-based pharmaceutical process development: a data-driven, mechanistic and hybrid model case study
- Benchmarking Affinity-Based Docking for Irreversible Acetylcholinesterase Inhibitors: A Physics-Informed Reactivity Framework for Stereoselective Potency Prioritization
- A predictive transferability index for crystal plasticity framework selection: Variational derivation, analytical bounds, and FFT-based plausibility assessment
- Analytical validation in catalytic CO2 conversion: Product identification, carbon accounting, and evidence for process performance
- Autoencoder-Based Dempster-Shafer Decision-Making Framework for Intelligent Process Monitoring: Applications to Nonlinear Chemical Processes
BibTeX
@misc{sandler2026evidencegraded,
title = {{An Evidence-Graded Framework for Pharmaceutical Route Selection and Process-Risk Prioritization: A PN6047 Case Study}},
author = {Leon Sandler},
howpublished = {ChemRxiv},
year = {2026},
month = oct,
doi = {10.26434/chemrxiv.15010156/v1},
url = {https://chemrxiv.org/doi/full/10.26434/chemrxiv.15010156/v1},
note = {CC BY},
}
RIS
TY - UNPB
TI - An Evidence-Graded Framework for Pharmaceutical Route Selection and Process-Risk Prioritization: A PN6047 Case Study
AU - Leon Sandler
PY - 2026
DA - 2026/10/09
PB - ChemRxiv
DO - 10.26434/chemrxiv.15010156/v1
UR - https://chemrxiv.org/doi/full/10.26434/chemrxiv.15010156/v1
AB - Purpose: To develop and demonstrate an evidence-graded framework for screening discovery-scale synthetic routes before experimental process development, using the publicly disclosed route to PN6047, a clinical-stage δ-opioid receptor agonist, as a case study. Methods: No synthesis was performed. Operations exemplified in two patent documents were inventoried; each transformation and its conditions were graded A–D by the strength of public evidence; documented regulatory and hazard attributes were flagged; two process-oriented variants were screened by step count, flags and an evidence-weighted validation burden; and a twelve-item risk register was ranked, with the sensitivity of the prioritization to the author-assigned ratings tested by perturbation. Results: The exemplified route (milligram to gram scale; final N-functionalization isolated in 16% by preparative HPLC) carries 11 documented flags, including an ICH Q3C Class 1 solvent, palladium and a benzotriazole-derived coupling reagent. Variants R1 and R2 carry 3 flags each but a higher validation burden (11 and 15 against 2, linear scale): fewer documented flags did not mean lower development uncertainty. Two risks, impurity purge when crystallization replaces chromatography and the undisclosed route to the vinyl bromide, stayed in the top three in about 87% of perturbations, conditional on the initial risk model. Conclusion: The framework converts public route information into an auditable experimental-prioritization strategy while explicitly separating documented process liabilities from unvalidated alternatives. It does not select a best route; it shows where the evidence is strong or assumed and which experiments carry the highest information value.
ER -